您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策

联系我们

400-009-0050

北京热线:010-82863481
13436696826
上海热线:021-64871266
021-64872612
传 真: 010-82601570
021-64872324

您当前的位置:首页>>研究报告>>医疗设备

医疗设备主要企业系列:无针注射器的主要制造商
Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022

医疗设备主要企业系列:无针注射器的主要制造商
【报告编号】:No.2740
【发布时间】:2012-09
【关 键 字】:
【报告页数】:
【报告价格】:电子版:2739美元
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481 13436696826
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 医疗设备行业的相关报告

目录

Abstract

‘Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022’ analyses the top 14 companies involved in the needle free injection (NFI) device market. This report also provides sales forecasts, market share analyses, discussions of technological developments and analyses of commercial drivers and restraints, including SWOT analysis of the overall NFI device market. There are over 38 tables and figures included. The result is comprehensive profiles on the leading companies operating in the NFI device market with detailed analyses and informed opinion to benefit your work. Visiongain has determined that the value of the global Needle-Free Injection Device market will reach $4.49bn in 2022.

What makes this report unique?

Visiongain consulted widely with industry experts and full transcripts from these exclusive interviews are included in the report. As such, our reports have a unique blend of primary and secondary sources providing informed opinion. The report provides insight into key drivers and restraints facing the industry, as well as identifying leading companies. The report also provides a unique blend of qualitative analysis combined with extensive quantitative data including global, submarket and national markets forecasts from 2012-2022 - all highlighting key business opportunities.

Why you should buy Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022

  • 93 pages of comprehensive analysis
  • 3 Exclusive Visiongain interviews with experts from:
    • Zogenix
    • Bioject Medical Technologies
    • Glide Pharma
  • 38 tables, charts, and graphs
  • Global Needle-Free Injection Device market forecast between 2012-2022
  • 2 Needle-Free Injection Device submarket forecasts from 2012-2022
    • Jet Injectors
    • Competing Technologies
  • A SWOT analysis
  • Several leading companies identified and 14 profiled: Zogenix, Bioject, Activa, J-Tip, Medical International Technology, Eurojet Medical, Pharmajet, D'Antonio Consultants, Glide Pharma, Crossject, Valeritas, Akra Dermojet, Penjet, Antares Pharma.

You can order this report today

Gain an understanding of the overall NFI device market and the leading companies operating in this market by ordering Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2012-2022.
Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Leading NFI Device Manufacturers: Overview of Findings
  • 1.2. Chapter Outline
  • 1.3. Research and Analysis Methods
  • 1.4. Aims, Scope and Format of the Report
  • 1.5. Glossary of Terms Related to the Report

2. Introduction to Needle-Free Technology

  • 2.1. What is Needle-Free Delivery?
    • 2.1.1. History
  • 2.2. Current Needle-Free Devices
  • 2.3. Rationale for Needle-Free Injections
  • 2.4. Applications of Needle Free Drug Delivery
    • 2.4.1. Pain Management
    • 2.4.2. Vaccine Delivery
    • 2.4.3. Insulin Delivery
    • 2.4.4. Paediatrics
  • 2.5. Regulation of Needle-Free Delivery Devices
    • 2.5.1. The US Regulation System
    • 2.5.2. The European Regulation System
  • 2.6. Advantages And Disadvantages of Needle Free Systems

3. The Global Needle Free Injection Device Market, 2011-2022

  • 3.1. The Global Needle-Free Injection Device Market, 2011
    • 3.1.1. The Global Needle Free Injection Device Market Forecast, 2012-2022
    • 3.1.2. Needle-Free Injection Devices: Industry Trends, 2012-2022
  • 3.2. The Jet Injector Device Market, 2011
    • 3.2.1. The Global Jet Injector Device Market Forecast, 2012-2022
    • 3.2.2. Jet Injector Devices: Industry Trends, 2012-2022
  • 3.3. The Global Competing Technologies Market, 2011
    • 3.3.1. The Global Competing Technologies Market Forecast, 2012-2022
    • 3.3.2. Competing Technologies: Industry Trends, 2012-2022
      • 3.3.2.1. Microneedle Technology
      • 3.3.2.2. Metered Dose Inhalers

4. The Leading North American Needle-Free Injection Device Manufacturers, 2012

  • 4.1. Antares Pharma
    • 4.1.1. Sales and Recent Performance Analysis, 2011
      • 4.1.1.1. Product Sales
    • 4.1.2. Technology
      • 4.1.2.1. Pressure Assisted Injection Devices
      • 4.1.2.2. Transdermal Gel System
    • 4.1.3. Products
      • 4.1.3.1. Vision
      • 4.1.3.2. Vibex
      • 4.1.3.3. Pen Injector
    • 4.1.4. Pipeline Technologies
      • 4.1.4.1. Vibex MTX
    • 4.1.5. Manufacturing
  • 4.2. Bioject Medical Technologies
    • 4.2.1. Sales And Recent Performance Analysis, 2011
    • 4.2.2. Technology
    • 4.2.3. Products
      • 4.2.3.1. Biojector 2000
      • 4.2.3.2. Vitajet
      • 4.2.3.3. ZetaJet
    • 4.2.4. Pipeline Technologies
      • 4.2.4.1. Intradermal Pen Injector
      • 4.2.4.2. Iject
      • 4.2.4.3. Jupiter Jet
    • 4.2.5. Manufacturing
    • 4.2.6. Collaborations
      • 4.2.6.1. MPI Research
      • 4.2.6.2. World Health Organisation (WHO)
  • 4.3. Zogenix
    • 4.3.1. Sales and Recent Performance Analysis, 2011
    • 4.3.2. Technology
      • 4.3.2.1. Applications
    • 4.3.3. Products
      • 4.3.3.1. Sumavel DosePro
    • 4.3.4. Pipeline Technologies
      • 4.3.4.1. Relday
    • 4.3.5. Collaborations
    • 4.3.6. Manufacturing
  • 4.4. Activa Brand Products, Inc.
    • 4.4.1. Technology
    • 4.4.2. Products
      • 4.4.2.1. Product Advantages
      • 4.4.2.2. Product Indications
  • 4.5. D'Antonio Consultants International Inc. (DCI)
    • 4.5.1. Products
      • 4.5.1.1. LectraJet
    • 4.5.2. Pipeline Technologies
      • 4.5.2.1. Low Workload Jet Injector
      • 4.5.2.2. Multi Channel Jet Injector (Simultaneous Vaccine Delivery)
  • 4.6. National Medical Products, Inc.
    • 4.6.1. Products
      • 4.6.1.1. J-Tip
    • 4.6.2. Advantages of the J-Tip System
  • 4.7. Medical International Technologies (MIT)
    • 4.7.1. Products
      • 4.7.1.1. MED-JET
    • 4.7.2. Increased Awareness Through Globalisation
  • 4.8. Penjet Corporation
    • 4.8.1. Products
      • 4.8.1.1. Penjet
    • 4.8.2. Applications
      • 4.8.2.1. Multi-Component Drugs
      • 4.8.2.2. Lyophilisation
      • 4.8.2.3. Small Pox Vaccination
  • 4.9. PharmaJet
    • 4.9.1. Technology
    • 4.9.2. Products
      • 4.9.2.1. STRATIS
    • 4.9.3. Applications
    • 4.9.4. Collaborations
  • 4.10. Valeritas
    • 4.10.1. Products
      • 4.10.1.1. Mini-Ject

5. The Leading European Needle-Free Injection Device Manufacturers, 2012

  • 5.1. Akra Dermojet
    • 5.1.1. Products
      • 5.1.1.1. Dermojet "HR"
      • 5.1.1.2. DERMOJET Polymedical
      • 5.1.1.3. Automatic DERMOJET
  • 5.2. Crossject Medical Technology
    • 5.2.1. Technology
    • 5.2.2. Products
      • 5.2.2.1. Zeneo
  • 5.3. Eurojet Medical
    • 5.3.1. Products
      • 5.3.1.1. E-Jet 100
  • 5.4. Glide Pharma
    • 5.4.1. Products/Technology
      • 5.4.1.1. Glide SDI
      • 5.4.1.2. Applications
    • 5.4.2. Advantages
      • 5.4.2.1. Injecting Solid Formulations
      • 5.4.2.2. Pharmaceutical Companies

6. SWOT Analysis of the Needle Free Injection Device Market, 2012

  • 6.1. Needle Free Injection Devices: Industry Trends
    • 6.1.1. Drivers
      • 6.1.1.1. Move Towards Safer Alternatives
      • 6.1.1.2. Patent Expiry Will Increase Competition
      • 6.1.1.3. Booming Global Vaccines Market
    • 6.1.2. Restraints
      • 6.1.2.1. Expensive Technology
      • 6.1.2.2. Limited Clinical Data
      • 6.1.2.3. Regulatory Bodies
  • 6.2. SWOT Analysis of the Needle-Free Delivery Market
    • 6.2.1. Strengths
      • 6.2.1.1. Reduced Pain on Injection
      • 6.2.1.2. No Specialist Training Required For Delivery
      • 6.2.1.3. Reduction in Transport Costs
    • 6.2.2. Weaknesses
      • 6.2.2.1. Inefficient Manufacturing Process
      • 6.2.2.2. Off Patent/Generics Require Reformulating
    • 6.2.3. Opportunities
      • 6.2.3.1. Emerging Economies
      • 6.2.3.2. Mass Immunisation Programs
    • 6.2.4. Threats
      • 6.2.4.1. Inexpensive Needles and Syringes
      • 6.2.4.2. Limited Clinical Data

7. Opinions from Our Industry Survey

  • 7.1. Interview with Zogenix Technologies
    • 7.1.1. The Needle-Free Injection Device Market
    • 7.1.2. Zogenix's Portfolio/Technology
    • 7.1.3. The Future Needle-Free Injection Device Market
  • 7.2. Interview with Bioject Medical Technologies
    • 7.2.1. Current Market for Needle Free Injection Technologies
    • 7.2.2. Current Technologies
    • 7.2.3. Future Prospects for the Industry
  • 7.3 Interview with Glide Pharma
    • 7.3.1. Growth of the Needle Free Market
    • 7.3.2. Glide SDI and Other Technologies
    • 7.3.3. Market Demand and Future Outlook

8. Conclusions

  • 8.1. Zogenix Dominated the NFI Device Market in 2011
  • 8.2. The Rise of Generics
  • 8.3. Strong Pipeline Will Help Drive the Market
  • 8.4. Concluding Remarks

Appendix A

  • About Visiongain

Appendix B

  • Visiongain report evaluation form

List of Tables

  • Table 2.1: Examples Of Needle-Free Vaccine Delivery Systems, 2012
  • Table 2.2: Examples Of Needle-Free Insulin Delivery Systems, 2012
  • Table 2.3: Advantages & Disadvantages of Needle-Free Injection, 2012
  • Table 3.1: Net Sales ($bn) and Market Shares (%) Of The Global Needle-Free Injection Device Market, By Technology, 2011
  • Table 3.2: Global Needle-Free Injection Devices: Market Forecast ($bn), 2011-2022
  • Table 3.3: Classification of Jet Injector Devices, 2012
  • Table 3.4: Global Needle-Free Jet Injection Devices: Market Forecast ($bn), 2011-2022
  • Table 3.5: Global Competing Needle-Free Technologies: Market Forecast ($bn), 2011-2022
  • Table 4.1: Antares Pharma: Net Sales ($m) & Market Shares (%), By Business, 2011
  • Table 4.2: Antares Pharma: Net Sales ($m) & Market Shares (%), By Product, 2011
  • Table 4.3: Antares Pharma Licensing Partnerships, 2012
  • Table 4.4: Antares Pharma: Summary of Technology
  • Table 4.5: Bioject: Net Sales ($m) and Market Shares (%), By Product Line, 2010
  • Table 4.6: Bioject: Summary of Technologies
  • Table 4.7: Zogenix: Net Sales ($m) and Market Shares (%), By Business, 2011
  • Table 4.8: Zogenix: Summary of Technology
  • Table 5.1: Akra Dermojet: Summary of Technology
  • Table 6.1: Drivers and Restraints For the Needle-Free Injection Device Market, 2012-2022
  • Table 6.2: Leading Drugs With Patent Expiration in 2012
  • Table 6.3: SWOT Analysis of the Needle-Free Injection Device Market, 2012-2022

List of Figures

  • Figure 3.1: Net Sales ($bn) Of The Global Needle-Free Injection Device Market, By Technology, 2011
  • Figure 3.2: Market Shares (%) Of The Global Needle-Free Injection Device Market, By Technology, 2011
  • Figure 3.3: Global Needle-Free Injection Devices: Market Forecast ($bn), 2011-2022
  • Figure 3.4: Global Needle-Free Jet Injection Devices: Market Forecast ($bn), 2011-2022
  • Figure 3.5: Global Competing Needle-Free Technologies: Market Forecast ($bn), 2011-2022
  • Figure 4.1: Antares Pharma: Market Shares (%), By Business, 2011
  • Figure 4.2: Antares Pharma: Net Sales ($m), By Product Group, 2011
  • Figure 4.3: Antares Pharma: Market Shares (%), By Product, 2011
  • Figure 4.4: Antares Pharma: Net Sales ($m), By Quarter, 2011
  • Figure 4.5: Bioject: Net Sales ($m), By Product Line, 2010
  • Figure 4.6: Bioject: Market Share (%), By Product Line, 2010
  • Figure 4.7: Bioject: Market Shares (%), By Geography, 2010
  • Figure 4.8: Bioject: Total Net Sales ($m), 2006-2011
  • Figure 4.9: Zogenix: Net Sales ($m), By Business, 2011
  • Figure 4.10: Zogenix: Market Shares (%), By Business, 2011
  • Figure 4.11: Zogenix: Net Sales ($m), By Quarter, 2011
  • Figure 6.1: The Transport Process for A Vaccine
  • Figure 8.1: Net Sales ($m) for Zogenix, Antares Pharma & Bioject, 2011

Companies Listed

  • Activa (Advantajet)
  • Akra Dermojet
  • Antares Pharma
  • Astellas Pharma
  • AstraZeneca
  • Battelle
  • Bioject Medical Technologies
  • BioValve Technologies
  • Bristol-Myers Squibb
  • Covidien
  • Crossject Medical technology
  • D'Antonio Consultants International
  • Diabetes Management International
  • Dr. Reddy's Laboratories
  • Durect
  • Echo Therapeutics
  • Eli Lilly & Co
  • Eurojet Medical
  • Ferndale Pharma Group
  • Ferring Pharmaceuticals
  • Glide Pharma
  • GlaxoSmithKline (GSK)
  • JCR Pharmaceuticals
  • Mallinckrodt
  • Medical International Technologies
  • Merck Serono
  • MGlas AG
  • Minnesota Rubber and Plastics (MRP)
  • MPI Research
  • National Medical Products
  • Nektar Therapeutics
  • Nova Nordisk
  • Novartis
  • Nypro Limited
  • Patheon
  • Penjet Corporation
  • Pfizer
  • PharmaJet
  • Sanofi-Pasteur
  • Takeda
  • Teva Pharmaceuticals
  • Valeritas
  • Zogenix

Government Agencies and Other Organisations Mentioned in This Report

  • FDA
  • WHO
  • UN
  • CDRH
  • EU
  • USAMRIID
  • PATH
  • CDC
医疗设备主要企业系列:无针注射器的主要制造商是由出版商Visiongain在2012年09月所出版的。这份市场调查报告书包含99 Pages 价格从美金2739起跳。
本网页内容可能与最新版本有所差异。详细情况请与我们联系。

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统